Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.

Reina KamedaHiroshi NomotoKyu Yong ChoShinichiro KawataKazuno OmoriJun TakeuchiSo NagaiYoshio KuriharaShin AokiAkinobu NakamuraTatsuya AtsumiHideaki Miyoshi

Published in: BMJ open (2020)

The University Hospital Medical Information Network (UMIN000031451); Japan Registry of Clinical Trials (jRCTs011180019); Pre-results.

Keyphrases

clinical trial
blood pressure
open label
study protocol
double blind
placebo controlled
phase ii
randomized controlled trial
hypertensive patients
phase iii
healthcare
heart rate
phase ii study
health information
obstructive sleep apnea
squamous cell carcinoma
sleep apnea
depressive symptoms
cross sectional